Effective targeting of prostate cancer by lymphocytes redirected by a PSMA×CD3 bispecific single-chain diabody

Prostate

Volumn 71, Issue 6, 2011, Pages 588-596

  Fortmüller, Kerstin ^a,b   Alt, Karen ^a,b   Gierschner, Dorothee ^a   Wolf, Philipp ^a   Baum, Volker ^a,b   Freudenberg, Nikolaus ^a   Wetterauer, Ulrich ^a   Elsässer Beile, Ursula ^a   Bühler, Patrick ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

bispecific diabody; immunotherapy; prostate cancer; PSMA CD3 bsc diabody; T cell redirecting

Indexed keywords

BIOLOGICAL MARKER; BISPECIFIC ANTIBODY; CANCER ANTIBODY; CD3 ANTIBODY; CD3 ANTIGEN; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN CD3 BISPECIFIC DIABODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOLYSIS; DRUG PROTEIN BINDING; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IN VITRO STUDY; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, SURFACE; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL GROWTH PROCESSES; ESCHERICHIA COLI; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952380566     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21274     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71-96. (Pubitemid 351521864)
2. Ghosh A, Heston WD,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91 (3): 528-539.
3. Segal DM, Weiner GJ, Weiner LM,. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11 (5): 558-562. (Pubitemid 29462132)
4. Holliger P, Hudson PJ,. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23 (9): 1126-1136. (Pubitemid 41486394)
5. Buhler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, Schamel WW, Elsasser-Beile U,. Target-dependent T-cell activation by coligation with a PSMA×CD3 diabody induces lysis of prostate cancer cells. J Immunother 2009; 32 (6): 565-573.
6. Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U,. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008; 57 (1): 43-52. (Pubitemid 350043647)
7. Wolf P, Alt K, Wetterauer D, Buhler P, Gierschner D, Katzenwadel A, Wetterauer U, Elsasser-Beile U,. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother 2010; 33 (3): 262-271.
8. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M,. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997; 10 (4): 445-453. (Pubitemid 27252636)
9. Mack M, Riethmüller G, Kufer P,. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 7021-7025.
10. Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P,. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and C D3: Tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 1997; 158 (8): 3965-3970. (Pubitemid 127488757)
11. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC,. A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95 (6): 2098-2103. (Pubitemid 30151651)
12. Haagen IA, de Lau WB, Bast BJ, Geerars AJ, Clark MR, de Gast BC,. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 1994; 39 (6): 391-396. (Pubitemid 24372405)
13. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA,. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100 (6): 690-697. (Pubitemid 34832980)
14. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA,. MT110: Novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43 (8): 1129-1143. (Pubitemid 43063166)
15. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC,. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170 (8): 4397-4402. (Pubitemid 36428210)
16. Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, Knackmuss S, Little M,. Synergistic antitumor effect of bispecific CD19×CD3 and CD19×CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002; 169 (1): 137-144. (Pubitemid 34686129)
17. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG,. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule- overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100 (5): 1095-1103. (Pubitemid 38222871)
18. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA,. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 2005; 65 (7): 2882-2889. (Pubitemid 40490092)
19. Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P,. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009; 32 (4): 341-352.
20. Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, da Silva A, Locher M, Kischel R, Lutterbuse R, Kufer P, Baeuerle PA,. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for murine CD3. Cancer Immunol Immunother 2006; 55 (7): 785-796.
21. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I,. Humanization of the bispecific epidermal growth factor receptor×CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006; 12 (13): 4036-4042. (Pubitemid 44078091)
22. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P,. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321 (5891): 974-977.